Clinical Trial Update: Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial assessing residual anti-Xa activity after the last treatment dose of enoxaparin has completed and terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anticoagulants and Bleeding Disorders
• Regional Anesthesia Morbidity
• Surgery

Drugs mentioned

• Enoxaparin (enoxaparin sodium)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Anticoagulants and Bleeding Disorders, Surgery | Phase 4 | Status: TERMINATED | Results posted: 2023-10-05